Christophe Quéva
Chief Scientific Officer
Oncology
iTeos Therapeutics
Belgium
Biography
Christophe joined iTeos as Chief Scientific Officer in August 2015 and brings expertise gained from 20 years of experience in oncology and immuno-oncology drug discovery and development. After his Ph.D., at the Fred Hutchinson Cancer Research Center, he worked at AstraZeneca, Amgen, and Gilead Sciences. Christophe has led or supported drug discovery programs for Oncology and inflammatory diseases from target selection to commercial approval. Christophe brings extensive experience in antibody and bispecific antibody therapeutics gained though his roles in the collaborations with Abgenix, Micromet and Macrogenics. He has authored 26 peer-reviewed publications and is an inventor of 5 patents.
Research Interest
Oncology and Immuno-oncology drug discovery and development.
